Kalaris 10-Q: Material Weaknesses Persist, TH103 Phase 1b/2 Data Slipped to 2H 2027
KLRS is trading near its 52-week low of $1.78 (3.9% above the low).
Summary
Kalaris reported a $33.4 million nine-month loss and $82.9 million in cash that it says lasts into 2028, but disclosed that its material weaknesses in internal controls remain unremediated and pushed Phase 1b/2 TH103 data to the second half of 2027.
Key Events · Earnings and Guidance · KLRS
-
Material Weaknesses Remain Unremediated
Management concluded disclosure controls and procedures were not effective as of September 30, 2026, because the material weaknesses identified at December 31, 2025 had not been fully remediated. The filing warns these could result in a misstatement of substantially all accounts.
-
TH103 Phase 1b/2 Data Slipped to 2H 2027
A pilot-manufacturer drug substance batch failed the aggregation release specification in Q3 2026. A new batch is now expected in Q2 2027, pushing Phase 1b/2 data to the second half of 2027 and Phase 3 initiation to 2028.
-
Nine-Month Loss of $33.4 Million
Net loss was $33.4 million for the nine months ended September 30, 2026, matching the prior-year period. Operating cash burn was $33.2 million, and the accumulated deficit stood at $193.4 million.
-
Cash of $82.9 Million Funds Into 2028
Cash, cash equivalents and marketable securities totaled $82.9 million at September 30, 2026, down from $118.0 million at year-end 2025. Management expects this to fund operating expenses and capital expenditures into 2028.
Analysis · KLRS · Life Sciences
The quarter itself is unremarkable: a $33.4 million nine-month loss and $82.9 million of cash that management says funds operations into 2028. What matters is what the 10-Q adds beyond this morning's press release. Management concluded disclosure controls were NOT effective as of September 30, 2026, because the previously identified material weaknesses in internal control over financial reporting remain unremediated. For a company that just hired a CFO in July 2026 and is asking investors to trust a single-asset clinical story, an unresolved ICFR gap is a real governance overhang. Separately, a failed drug-substance batch at the pilot manufacturer pushed Phase 1b/2 data to the second half of 2027 and Phase 3 initiation to 2028, roughly a year of lost timeline on the only asset that matters. The stock already trades near its 52-week low of $1.78 against a $11.88 high, so the market has been pricing much of this in, but the formal control conclusion and the concrete delay dates are new, documented facts.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KLRS was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.4M. The 52-week trading range was $1.78 to $11.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.